About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01749397

A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Study identifier: NCT01749397
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Metastatic epithelial ovarian, primary peritoneal, or fallopian tube cancer for which standard curative measures do not exist, no prior PARP inhibitor.

Type of study:

Phase I study

Treatment:

21-day cycles with veliparib intravenously on days 1-10 and floxuridine intraperitoneal on days 3-5

Study sites:

Maryland
Baltimore
Johns Hopkins University
Contact: Deborah K. Armstrong 410-955-8804 jhcccro@jhmi.edu
Principal Investigator: Deborah K. Armstrong

Minnesota
Rochester
Mayo Clinic
Contact: Andrea E. Wahner Hendrickson 507-284-2511 wahnerhendrickson.andrea@mayo.edu

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org